Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05758688 · ClinicalTrials.gov registry record · Phase 2
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
A Phase 2 study of Endometrial Cancer and Cervical Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 3
- Study locations
NCT05758688 is a Phase 2 study of Endometrial Cancer and Cervical Cancer that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 25 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05758688, a Phase 2 study of Endometrial Cancer and Cervical Cancer, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a single institution, multi-center, Phase II, single-arm study, using Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) in the post-surgical, adjuvant setting for definitive treatment of gynecologic cancers. The purpose of this study is to estimate rate of acute clinician-reported gastrointestinal (GI) toxicity using WP PBS PRT in the definitive treatment of gynecologic cancers in the post-surgical, adjuvant setting.
Conditions Studied
Interventions
- RADIATION Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT)
Study Locations (3)
Pennsylvania
- Lancaster General Health - Ann B. Barshinger Cancer Institute - Lancaster
- University of Pennsylvania - Philadelphia
New Jersey
- Virtua Health - Voorhees Township
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-11-06 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05758688
The ClinicalTrials.gov registry entry for NCT05758688 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) is the first listed.
NCT05758688 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05758688 about?
NCT05758688 is a clinical study titled "PROton Therapy for Post Surgical Treatment of GYNecologic Cancer". This is a single institution, multi-center, Phase II, single-arm study, using Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) in the post-surgical, adjuvant setting for definitive treatment of gynecologic cancers. The purpose of this study is to estimate rate of acute clinician-rep...
What is the current status of trial NCT05758688?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2023-11-06. Estimated completion is 2026-11.
What conditions does trial NCT05758688 study?
This clinical trial studies the following conditions: Endometrial Cancer, Cervical Cancer, Uterine Cancer.
What interventions are being tested in trial NCT05758688?
The interventions under investigation include: Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) (RADIATION).
Who is sponsoring clinical trial NCT05758688?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05758688 being conducted?
This trial has 3 study locations across New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.